Across the reviews, there was little to no difference between these drugs and placebo for major cardiovascular events, quality of life, or mortality
At that point, weight was still declining the curve had not plateaued, suggesting even greater reductions may be possible with longer treatment
doi: 10.3390/ani14050714 231 Prez-PascualD.Prez-CobasA
In both studies, tesamorelin-treated patients completing the 26-week treatment period were re-randomized to blinded therapy with either daily placebo or 2 mg tesamorelin for an additional 26-week treatment period (Extension Phase) in order to assess maintenance of VAT reduction and to gather long-term safety data
However, a randomized controlled trial by Donnell et al
Compounded semaglutide cannot match these timelines because it lacks the proprietary stabilizers in brand-name products